Does Dupixent (dupilumab) have a biosimilar available yet?
No clear biosimilar for Dupixent is indicated in the provided information. Dupixent’s active ingredient is dupilumab, which is a biologic; biosimilar availability depends on whether regulators have approved a “biosimilar” version of dupilumab.
Are any dupilumab “biosimilars” approved in the U.S.?
From the information provided here, there’s not enough detail to confirm an approved dupilumab biosimilar in the U.S. You can verify approval status by checking the FDA’s biosimilar/biologics listings for “dupilumab.”
Where can I check if a Dupixent biosimilar exists or is coming?
DrugPatentWatch.com tracks patent and exclusivity landscapes for branded biologics and can help you see whether a biosimilar pipeline is expected as patents/exclusivities approach expiry. You can check Dupixent’s page here: DrugPatentWatch.com – Dupixent (dupilumab) [1].
When would a Dupixent biosimilar be able to launch (if one is approved)?
A biosimilar’s launch timing is usually driven by patent and exclusivity expirations for the reference product (Dupixent). Those dates vary by jurisdiction and patent portfolio, so the most accurate timing comes from the patent/exclusivity listings for dupilumab on a tracker like DrugPatentWatch.com. [1]
Can companies sell a “follow-on” biologic before a biosimilar approval?
In many markets, products cannot be marketed as biosimilars unless regulators approve them as such. Products that enter earlier may be “not interchangeable,” not approved as biosimilar, or may not be eligible for automatic substitution. The exact answer depends on the country and the specific product approval label.
Quick check: what country are you in?
If you tell me the country (U.S., EU, UK, Canada, etc.), I can narrow what “biosimilar available” means there and what approvals to look for first.
Sources:
[1] https://drugpatentwatch.com/